Krka, d. d., Novo mesto stock (SI0031102120): Ljubljana shares steady after recent FY 2025 dividend move

Krka, d. d., Novo mesto shares in Slovenia traded quietly on the Ljubljana Stock Exchange on 06/02/2026, as investors continued to digest the Slovenian drug maker’s recently approved FY 2025 dividend proposal and latest operating update.

Krka, d. d., Novo mesto, the Slovenian generic pharmaceuticals group, saw its shares trade sideways on the Ljubljana Stock Exchange on 06/02/2026 as the market continued to process the company’s most recent dividend proposal for the 2025 financial year and the latest operating performance trends disclosed in its official filings, according to Ljubljana Stock Exchange data as of 06/02/2026.

The stock traded at EUR 117.00 on 06/02/2026 on the Ljubljana Stock Exchange, according to Ljubljanska borza data as of 06/02/2026. In Germany, the shares changed hands on Tradegate at around EUR 116.50 on 06/02/2026 based on platform price data as of that date. Krka is one of the larger Slovenian constituents in the local blue-chip index SBI TOP, giving it prominence among domestic and regional equity investors.

At the company’s annual general meeting for FY 2025, the management and supervisory boards proposed a dividend that reflected the group’s profitability and cash generation in 2025, as reported in Krka’s investor relations material published in 2026. The proposed payout follows the established policy of returning a portion of net profit to shareholders while still funding capital expenditure and international expansion. The AGM notice indicated that the dividend would be payable in euros to shareholders of record on the designated cut-off date once approved by the meeting.

Operationally, Krka reported that its pharmaceuticals and healthcare products business continued to generate most of its revenue in Europe, especially in Central and Eastern Europe and in the Russian Federation and CIS region, while also expanding in Western Europe markets such as Germany, Spain, and France, according to its most recent annual and quarterly reports released in 2025 and early 2026. The company highlighted demand for key products across therapeutic areas including cardiovascular, central nervous system, and gastrointestinal treatments, as well as its animal health portfolio.

According to Krka’s 2025 annual report and 2026 first-quarter update, the company also emphasized disciplined cost control and investment into development and production to support long-term competitiveness. Management pointed to stable or rising sales volumes in several core markets despite pricing pressure typical for generic medicines, along with continued efforts to optimize its product mix and develop new generic formulations.

As of: 06/02/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Krka
• Sector/industry: Pharmaceuticals and generic drugs
• Headquarters/country: Novo mesto, Slovenia
• Core markets: Central and Eastern Europe, Western Europe, Russia and CIS
• Key revenue drivers: Generic prescription medicines, over-the-counter products, and animal health treatments
• Home exchange/listing venue: Ljubljana Stock Exchange (KRKG)
• Trading currency: EUR

Krka, d. d., Novo mesto: core business model

Krka focuses on developing, manufacturing, and marketing generic pharmaceuticals and related health products aimed at human and animal use, with revenue primarily generated through prescription generics, selected over-the-counter brands, and veterinary medicines sold across Europe and key international markets.

Latest quarterly results for Krka, d. d., Novo mesto at a glance

For the first quarter of 2026, Krka reported revenue of approximately EUR 500 million and net profit of around EUR 120 million, according to its Q1 2026 report published on the investor relations section of its website on 05/15/2026. The company indicated that sales growth was supported by higher volumes in Central and Eastern Europe and steady demand in Western Europe, while exchange rate movements and pricing pressure continued to influence reported figures.

The Q1 2026 update also showed that Krka maintained a solid balance sheet with low net debt and continued to invest in production capacity and research and development, in line with its strategy to broaden its product portfolio and geographic footprint, as detailed in the same filing. Management confirmed that the group remained committed to its long-term dividend policy and capital investment plans, linking these priorities to the strong cash flow generation recorded in the period.

Conclusion

Krka, d. d., Novo mesto shares on the Ljubljana Stock Exchange traded steadily on 06/02/2026 as investors weighed the company’s FY 2025 dividend proposal and the solid operating metrics reported for Q1 2026. The latest quarterly figures underline the Slovenian group’s continued reliance on demand for generic pharmaceuticals across Europe and other key regions, paired with a conservative financial profile. How the balance between ongoing investment in capacity and research and the cash distributions to shareholders evolves will remain an important theme for market participants following the stock over the coming quarters.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.